JPWO2021189104A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021189104A5 JPWO2021189104A5 JP2022554199A JP2022554199A JPWO2021189104A5 JP WO2021189104 A5 JPWO2021189104 A5 JP WO2021189104A5 JP 2022554199 A JP2022554199 A JP 2022554199A JP 2022554199 A JP2022554199 A JP 2022554199A JP WO2021189104 A5 JPWO2021189104 A5 JP WO2021189104A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antisense oligomer
- ace2
- composition according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000692 anti-sense effect Effects 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 30
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 claims description 20
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 241000711573 Coronaviridae Species 0.000 claims description 4
- 108010029485 Protein Isoforms Proteins 0.000 claims description 4
- 102000001708 Protein Isoforms Human genes 0.000 claims description 4
- 101150054399 ace2 gene Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 4
- 229940035893 uracil Drugs 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 102100034343 Integrase Human genes 0.000 claims description 2
- 101710203526 Integrase Proteins 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000021615 conjugation Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 229940113082 thymine Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 1
- 102220559429 T-cell-interacting, activating receptor on myeloid cells protein 1_H14A_mutation Human genes 0.000 description 1
- 102220559459 T-cell-interacting, activating receptor on myeloid cells protein 1_H17A_mutation Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020900883A AU2020900883A0 (en) | 2020-03-23 | Antisense Oligomers for Treatment of Disease | |
| AU2020900883 | 2020-03-23 | ||
| PCT/AU2021/050261 WO2021189104A1 (en) | 2020-03-23 | 2021-03-22 | Antisense oligomers for treatment of disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023519518A JP2023519518A (ja) | 2023-05-11 |
| JPWO2021189104A5 true JPWO2021189104A5 (https=) | 2024-03-12 |
| JP2023519518A5 JP2023519518A5 (https=) | 2024-03-12 |
Family
ID=77889846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554199A Pending JP2023519518A (ja) | 2020-03-23 | 2021-03-22 | 疾患の処置のためのアンチセンスオリゴマー |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230407309A1 (https=) |
| EP (1) | EP4127174A4 (https=) |
| JP (1) | JP2023519518A (https=) |
| CN (1) | CN115397988A (https=) |
| AU (1) | AU2021244774A1 (https=) |
| WO (1) | WO2021189104A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7722666B2 (ja) * | 2020-07-28 | 2025-08-13 | 神戸天然物化学株式会社 | アンギオテンシン変換酵素２遺伝子のエクソンのスキッピングを誘導するアンチセンス核酸 |
| US20240067973A1 (en) * | 2020-12-31 | 2024-02-29 | The First Affiliated Hospital Of Sun Yat-Sen University | Oligonucleotide for reducing the expression of angiotensin-converting enzyme 2 (ACE2) and its use for treating viral infection |
| CA3256035A1 (en) * | 2022-04-14 | 2023-10-19 | Invisishield Technologies Ltd. | COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS |
| US20250333744A1 (en) * | 2022-04-14 | 2025-10-30 | Shift Pharmaceuticals Holding Inc. | Polynucleotide Treatments for Charcot-Marie-Tooth Disease |
| WO2023201306A1 (en) | 2022-04-14 | 2023-10-19 | Invisishield Technologies Ltd. | Compositions for preventing or treating influenza infections |
| WO2024233583A2 (en) * | 2023-05-08 | 2024-11-14 | Carisma Therapeutics Inc. | Compositions and methods relating to intronic shrna chimeric antigen receptor constructs |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610497B1 (en) * | 1997-12-11 | 2003-08-26 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
| US6989363B1 (en) * | 1997-12-11 | 2006-01-24 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
| US20050203038A1 (en) * | 2004-03-10 | 2005-09-15 | Isis Pharmaceuticals Inc. | Modulation of ACE2 expression |
| US20070185044A1 (en) * | 2005-03-08 | 2007-08-09 | Dobie Kenneth W | Modulation of ace2 expression |
| EP1857548A1 (en) * | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
| CN111979273B (zh) * | 2020-08-24 | 2022-05-27 | 苏州启辰生物科技有限公司 | 一种制备人源化ace2小鼠模型的方法 |
-
2021
- 2021-03-22 US US17/909,947 patent/US20230407309A1/en active Pending
- 2021-03-22 WO PCT/AU2021/050261 patent/WO2021189104A1/en not_active Ceased
- 2021-03-22 AU AU2021244774A patent/AU2021244774A1/en active Pending
- 2021-03-22 EP EP21776876.1A patent/EP4127174A4/en not_active Withdrawn
- 2021-03-22 CN CN202180023548.6A patent/CN115397988A/zh active Pending
- 2021-03-22 JP JP2022554199A patent/JP2023519518A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7442574B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| EP2850186B1 (en) | Compositions and methods for modulating smn gene family expression | |
| US20180312839A1 (en) | Methods and compositions for increasing smn expression | |
| EP3573618B1 (en) | Compositions and methods for hemoglobin production | |
| JP2015518710A (ja) | ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法 | |
| JP2015518712A (ja) | Ｍｅｃｐ２発現を調節するための組成物及び方法 | |
| US20150232836A1 (en) | Compositions and methods for modulating gene expression | |
| EP3033423A1 (en) | Epigenetic regulators of frataxin | |
| US20150141320A1 (en) | Compositions and methods for modulating gene expression | |
| JP2016528897A (ja) | Ｒｎａを調節するための組成物および方法 | |
| JP2015523853A (ja) | Ａｔｐ２ａ２発現を調節するための組成物及び方法 | |
| US10837014B2 (en) | Compositions and methods for modulating SMN gene family expression | |
| CN114555188A (zh) | 治疗apoc3相关疾病和病症的方法 | |
| WO2018058006A1 (en) | Oligonucleotides containing 2'-deoxy-2'fluoro-beta-d-arabinose nucleic acid (2'-fana) for treatment and diagnosis of retroviral diseases | |
| JPWO2021189104A5 (https=) | ||
| WO2022026648A1 (en) | Inhibition of incexact1 to treat heart disease | |
| JP2023513188A (ja) | 遺伝子の発現増加のためのｍｉｒｎａ－４８５阻害剤 | |
| WO2019178187A1 (en) | Compositions and methods for hemoglobin production | |
| US20190055553A1 (en) | Methods for identifying and targeting non-coding rna scaffolds | |
| KR100741374B1 (ko) | 동물에서 아데노바이러스의 증식을 억제하는 방법 | |
| CN101503437B (zh) | 核酸分子si-cypj-4及其在制备抗癌药物中的应用 | |
| RU2021134071A (ru) | Модуляторы и модуляция рнк рецептора конечных продуктов глубокого гликирования | |
| JP2024501762A (ja) | アンジオテンシン変換酵素２（ａｃｅ２）の発現を低減させるためのオリゴヌクレオチド、及びウイルス感染を処置するためのその使用 | |
| CN121513031A (zh) | S-腺苷甲硫氨酸或其盐在制备防治ato心毒性药物中的应用 | |
| WO2021133874A1 (en) | Compositions and methods for hemoglobin production |